“The report on Anthelmintic Drugs Market was recently published by SDKI, which includes the latest market trends, current and future opportunities along with the factors that are driving the growth of the market. This report further encompasses the records for the expansion of the market along with information on the investment opportunities that help the clients to take positive decisions on the parameters for gaining profitable revenues. Moreover, the report also contains identification and investigation of the market structure, in-depth qualitative analysis, restraints & challenges, growth drivers, emerging product trends & market opportunities and Porter’s five forces.

Download Sample of This Strategic Report: https://www.sdki.us/sample-request-110512

Anthelmintic Drugs Market: Overview

• According to the latest report on the global anthelmintic drugs market for the historical period 2023-2033 and forecast period 2023-2033, increase in incidence of helminth infection across the globe, innovative drug launch for gastrointestinal nematodes, government initiatives, and rise in pet ownership and spending on companion animals are expected to drive the global market during the forecast period.
• According to the report, the anthelmintic drugs market was valued at ~US$ 2 Bn in 2022 and is anticipated to expand at a CAGR of ~5% from 2023-2033

Increase in Incidence of Helminth Infection Worldwide: Key Drivers

• Rise in prevalence of helminth infections caused by roundworm, hookworm, whipworm, and others worms is anticipated to drive the need of anthelmintic drugs for the treatment of the same
• Soil transmitted helminth infections are caused by various species of parasitic worms. According to the WHO, as of March 2020, nearly 1.5 billion humans were suffering from soil transmitted helminth infection across the globe. This number accounts for 24% of the global human population. Major species increasing the disease burden are ascaris lumbricoides (roundworms), trichuris trichiura (whipworms), necator americanus, and ancylostoma duodenale (hookworms).
• According to the WHO data, in March 2022, distribution of soil-transmitted helminth infection was higher in sub-Saharan Africa, the Americas, China, and countries in Asia. Globally, 267 million preschool children and 568 million schoolchildren in the above areas are suffering from helminth infections.
• Moreover, S. stercoralis are estimated to be affecting around 600 million people globally. Poor hygiene and sanitation are the other factors boosting incidence of soil-transmitted helminth infections across the globe.

Government Initiatives to Boost Market Growth

• Initiatives and paradigm shift in focus of governments toward contributing in managing the helminth infections across the globe are anticipated to boost the market for anthelmintic drugs
• For instance, the National Deworming Day is a major initiative by the Ministry of Health and Family Welfare, Government of India, to make the country worm-free. According to the WHO, 241 million children in the age group 1 to 14 years are at a higher risk of parasitic intestinal worms in India. Hence, the government is likely to develop guidelines for creating awareness and eradicate helminth infection.
• Anthelmintic drugs are the primary controlling measure for eradicating worms in livestock. Annual cost of parasitic diseases is estimated to be US$ 1 Bn in Australia and US$ 7.11 Bn in Brazil. Hence, standard policies for treatment of worm infection in humans and livestock are of prime importance in every country.

Anthelmintic Drug Resistance to Hamper Market

• Anthelmintic drugs are the most preferred and efficient treatment for fighting helminthiasis in animals and humans. However, multidrug-resistance is a major concern in livestock, especially in the two new classes such as aminoacetonitrile derivatives and paraherquamide derivatives.
• Rise in multidrug-resistance would pressurize producers and animal health professionals to develop alternative methods of treatment. Thus, rise in drug resistance to most commonly prescribed anthelmintic drugs by parasitic helminths is likely to restrain the market during the forecast period. Helminthiasis has been reported to develop resistance to drugs such as Levamisole, morantel, Benzimidazole, Albendazole, Avermectin, and Ivermectinin the past few years.
• Resistance to anthelmintic drugs is a major concern in sheep-producing countries in Europe. Multidrug & multispecies resistance is increasing at a rapid pace in South America. This is anticipated to restrain the global anthelmintic drugs market. According to a research, resistance against monepantel and derquantel has already been reported, which has increased the risk factor associated with anthelmintic resistance.

Anthelmintic Drugs Market: Competition Landscape

• This report profiles major players in the global anthelmintic drugs market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
• The global anthelmintic drugs market is highly fragmented with the presence of a number of international as well as regional players
• Leading players operating in the global anthelmintic drugs market include 
  • Novartis AG
  • Cipla Inc.
  • Sun Pharmaceutical Industries Ltd
  • Amneal Pharmaceuticals LLC. (Impax Laboratories, Inc.)
  • Zoetis, Inc.
  • GlaxoSmithKline plc
  • Bayer AG
  • Merck & Co., Inc. (Intervet Inc.)
  • Boehringer Ingelheim International GmbH

Get a Sample Copy of the Report@ https://www.sdki.us/sample-request-110512

Anthelmintic Drugs Market: Key Developments

• Key players in the global anthelmintic drugs market are engaged in regulatory approval, launch of new products, and acquisition & collaborative agreements with other companies. These strategies are likely to fuel the growth of the global anthelmintic drugs market. A few expansion strategies adopted by players operating in the global anthelmintic drugs market are:
  • In February 2022, Zoetis received approval for Simparica Trio drug, a combination used as a prevention for heartworm disease, roundworms, ricks, hookworms, and fleas in dogs
  • In April 2022, Janssen Pharmaceuticals Inc. announced that WHO has prequalified the company’s new product VERMOX (Mebendazole) CHEWABLE for intestinal worms. After the WHO prequalification, this product is likely to be available for the children in the age group of 1 year, especially in high burden countries.
  • In May 2018, Amneal Pharmaceuticals LLC and Impax Laboratories, Inc. completed their merger to form a new company known as Amneal Pharmaceuticals, Inc. This merger is likely to boost the generic business making Amneal as a fifth-largest generic business in the U.S.
  • In September 2022, Cipla announced receiving final approval of the Abbreviated New Drug Application (ANDA) for Albendazole 200 mg tablet
• The report on the global anthelmintic drugs market discussed individual strategies, followed by company profiles of manufacturers of anthelmintic drugs. The competition landscape section has been included in the report to provide readers with a dashboard view of key players operating in the global anthelmintic drugs market.

Anthelmintic Drugs Market – Scope of the Report

The report on the global Anthelmintic Drugs Market studies the past as well as current growth trends and opportunities to gain valuable insights of these indicators for the market during the forecast period 2023-2033 The report provides the overall revenue of the global anthelmintic drugs market for the period 2023-2033, considering 2023 as the base year and 2033 as the forecast year. The report also provides the compound annual growth rate (CAGR) for the global anthelmintic drugs market for the forecast period.

The report has been prepared after an extensive research. Primary research involved bulk of research efforts, wherein analysts carried out interviews with industry leaders and opinion makers. Extensive secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the global anthelmintic drugs market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts also employed a combination of the top-down and bottom-up approaches to study various phenomena in the global anthelmintic drugs market.

The report delves into the competition landscape of the global anthelmintic drugs market. Key players operating in the global anthelmintic drugs market have been identified, and each one of these has been profiled for distinguishing business attributes. Company overview, financial standings, recent developments, and SWOT are some of the attributes of players profiled in the global anthelmintic drugs market report.

Key Questions Answered in Anthelmintic Drugs Market Report

• What is the sales/revenue generated by the global anthelmintic drugs market across all the regions during the forecast period?
• What are the key trends in the global anthelmintic drugs market?
• What are the major drivers, restraints, and opportunities in the global market?
• Which region is set to expand at the fastest CAGR during the forecast period?
• Which segment will have the highest revenue globally in 2033 and which drug class will expand at the fastest CAGR during the forecast period?

Anthelmintic Drugs Market – Research Objectives and Research Approach

The comprehensive report on the global anthelmintic drugs market begins with an overview of the market, followed by the scope and objectives of the study. Following this, the report provides detailed explanation of the objectives of the study and healthcare compliances laid down by accredited agencies in the purview of research in the global anthelmintic drugs market. It is followed by market introduction, market dynamics, and an overview of the global anthelmintic drugs market, which includes analysis of market drivers, restraints, and trends affecting the growth of the market. Furthermore, Y-o-Y analysis with elaborate insights has been provided to understand the Y-o-Y trends of the anthelmintic drugs market. The next section of the global anthelmintic drugs market report highlights the USPs, which include epidemiology of helminthic infections across globe, key industry events (product launches, approvals, acquisitions, mergers, collaborations, etc.), and impact of COVID-19 on the anthelmintic drugs market.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section further divided into smaller sections. The entire report comprises an exhaustive collection of graphs and tables that are appropriately interspersed in the entire compilation. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

For more information about this report visit: Anthelmintic Drugs Market“

Revenue generated by key anthelmintic drugs manufacturers has been mapped to ascertain the size of the global anthelmintic drugs market in terms of value. The forecast presented here assesses the total revenue generated in the anthelmintic drugs market. In order to provide an accurate forecast, we initiated by sizing up the current anthelmintic drugs market with the help of the parent market.

The report analyzes the global anthelmintic drugs market in terms of drug class, route of administration, application, target pathogen, distribution channel, and region. Key segments under each criteria have been studied at length, and the market share for each of these at the end of 2030 has been provided. These valuable insights would help market stakeholders in making informed business decisions for investments in the global anthelmintic drugs market.

About SDKI:

The dynamic nature of business environment in the current global economy is raising the need amongst business professionals to update themselves with current situations in the market. To cater such needs, Shibuya Data Count ( SDKI ) provides market research reports to various business professionals across different industry verticals, such as healthcare & pharmaceutical, IT & telecom, chemicals and advanced materials, consumer goods & food, energy & power, manufacturing & construction, industrial automation & equipment and agriculture & allied activities amongst others.

For more information, please contact:

Lauren Brown
Shibuya Data Count
Email: [email protected]
Tel: + 81 3 45720790